Literature DB >> 9702742

Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence.

E Duaux1, P Gorwood, N Griffon, M C Bourdel, F Sautel, P Sokoloff, J C Schwartz, J Ades, H Lôo, M F Poirier.   

Abstract

Anatomical, pharmacological and human post-mortem studies suggest the dopamine D3 receptor (DRD3) gene as a candidate for drug dependence. We thus performed an association study of the Bal I polymorphism at the DRD3 gene, including 54 opiate addicts and 70 controls. Opiate addicts had a higher sensation-seeking score (on the Zückerman scale) than controls (P = 0.001), particularly a subgroup (70%) who had a distinctly higher score, exceeding 24. There were no marked differences in genotypes between patients as a whole and controls. However, patients with a sensation-seeking score above 24 were more frequently homozygotes for both alleles than patients with a sensation-seeking score under 24 (P = 0.038) or controls (P = 0.034). Although obtained in a sample of limited size, these results suggest that the DRD3 gene may have a role in drug dependence susceptibility in individuals with high sensation-seeking scores. This hypothesis is consistent with the role of DRD3 in mediating responses to drugs of abuse in animals and the association of homozygosity at the Bal I polymorphism with drug abuse in schizophrenic patients (see companion article by Krebs et al).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9702742     DOI: 10.1038/sj.mp.4000409

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  23 in total

Review 1.  Genetic studies of alcoholism and substance dependence.

Authors:  T Reich; A Hinrichs; R Culverhouse; L Bierut
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

Review 2.  From dopaminergic genes to psychiatric disorders.

Authors:  Janet Hoenicka; María Aragüés; Guillermo Ponce; Roberto Rodríguez-Jiménez; Miguel A Jiménez-Arriero; Tomás Palomo
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 3.  An overview of the genetics of substance use disorders.

Authors:  H M Lachman
Journal:  Curr Psychiatry Rep       Date:  2006-04       Impact factor: 5.285

4.  Dopamine Genetics and Function in Food and Substance Abuse.

Authors:  K Blum; M Oscar-Berman; D Barh; J Giordano; Ms Gold
Journal:  J Genet Syndr Gene Ther       Date:  2013-02-10

5.  Genetic deletion of the dopamine D3 receptor increases vulnerability to heroin in mice.

Authors:  Jia Zhan; Chloe J Jordan; Guo-Hua Bi; Xiang-Hu He; Eliot L Gardner; Yan-Lin Wang; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2018-08-20       Impact factor: 5.250

Review 6.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

7.  Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variants.

Authors:  Orna Levran; Einat Peles; Matthew Randesi; Joel Correa da Rosa; Jurg Ott; John Rotrosen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Pharmacogenomics       Date:  2014-12       Impact factor: 2.533

8.  The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats.

Authors:  Krista Spiller; Zheng-Xiong Xi; Xiao-Qing Peng; Amy H Newman; Charles R Ashby; Christian Heidbreder; József Gaál; Eliot L Gardner
Journal:  Psychopharmacology (Berl)       Date:  2007-11-06       Impact factor: 4.530

9.  Dopamine D3 receptor Ser9Gly and catechol-o-methyltransferase Val158Met polymorphisms and acute pain in sickle cell disease.

Authors:  Ellie Jhun; Ying He; Yingwei Yao; Robert E Molokie; Diana J Wilkie; Zaijie Jim Wang
Journal:  Anesth Analg       Date:  2014-11       Impact factor: 5.108

10.  The dopamine D3 receptor and drug addiction.

Authors:  P Sokoloff; B Le Foll; S Perachon; R Bordet; S Ridray; J C Schwartz
Journal:  Neurotox Res       Date:  2001-10       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.